According to Todd Haim, chief of the Office of Small Business Research at the National Institute on Aging (NIA), Alzheimer’s disease (AD) is a major issue. In his opening remarks on a BIO Digital panel, titled “Brave Innovations: public and private solutions to advance Alzheimer’s therapeutics and diagnostics in a risk-averse climate,” he provided data showing why new treatments for AD and AD-related dementias (ADRD) are desperately needed.
The biotech industry's rapid response to COVID-19, a pivot of global scope, is driving a broad array of approaches to tackling the infection. On Monday, the first day of BIO's virtual convention, the trade group gathered some of the effort's leading voices to take stock of how those efforts are shaping up.
The biotech industry's rapid response to COVID-19, a pivot of global scope, is driving a broad array of approaches to tackling the infection. On Monday, the first day of BIO's virtual convention, the trade group gathered some of the effort's leading voices to take stock of how those efforts are shaping up. It put a spotlight on work underway at Athersys Inc., Regeneron Inc., SAB Biotherapeutics Inc., Takeda Pharmaceutical Co. Ltd. and Vir Biotechnology Inc.
When BIO 2019 closed its doors in Philadelphia last June, none of the delegates of the industry’s largest event would have predicted that the next meeting, scheduled for San Diego, would be canceled and the event would be transformed into a virtual version. In just a few months, the COVID-19 pandemic has decimated our normal way of life and, until effective therapeutics and vaccines become available, how we conduct the business of biotechnology will remain radically different. This will be one of the many themes explored during BIO Digital Week that kicked off today.
The juggernaut that is Daiichi Sankyo Co. Ltd.’s Enhertu continued to roll into this weekend’s American Society of Clinical Oncology virtual meeting, bringing momentum from its December FDA approval for HER2-positive breast cancer, along with fresh data from three new studies in other indications.
SUZHOU, China – With the outbreak tightly contained, business activities are starting to get back to normal in China. Opening in Suzhou on Thursday, the Enmore Bio Conference 2020 is one of the first industry galas to take place since the coronavirus hit the country. In the opening session, Chinese biotech insiders pointed to a bumpy road ahead for Chinese companies in the post-COVID-19 era.
SUZHOU, China – Chinese CAR T therapy developers from early to IPO-ready-stage are confident that they can create a strong presence in the global scene with their innovations, and they are also making strategies that will work best for their home market.
Overall, data presented at the American Society of Clinical Oncology virtual meeting over the weekend appear to have garnered investor approval, with the BioWorld Cancer index advancing 3%, by market close Monday, and a further 1.7% by the closing bell today.